Portola Pharmaceuticals is putting blood, sweat, and tears into developing new medications for blood disorders. The company has three drug candidates in the works that, if approved, will treat thrombosis (blood clots). Its lead candidate, Betrixaban, is an oral medication that would prevent certain types of blood clots in seriously ill patients. Betrixaban is currently in Phase 3 study. Another medication in development, PRT4445, would help with uncontrolled bleeding episodes after surgery, and PRT2070 is being developed for hematologic, or blood, cancers and inflammatory disorders. Another version of PRT2070 is being developed with Biogen. Founded in 2003, Portola Pharmaceuticals went public in 2013.